Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis

World Journal of Gastroenterology

Volumn 19, Issue 22, 2013, Pages 3481-3486

  Lv, Guo Cai ^a   Yao, Jin Mei ^a   Yang, Yi Da ^a   Zheng, Lin ^a   Sheng, Ji Fang ^a   Chen, Yu ^a   Li, Lan Juan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Alanine transaminase; Efficacy; Lamivudine; Liver cirrhosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; CREATININE; HEMOGLOBIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CHILD TURCOTTE PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PROTHROMBIN TIME; SCORING SYSTEM; SEROCONVERSION; UREA NITROGEN BLOOD LEVEL;

EID: 84879056884     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i22.3481     Document Type: Article

References (18)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [DOI: 10.1056/NEJMra031087]
2. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8 [DOI: 10.1055/s-2005-915644]
3. Huber R, Orzeszyna M, Pokorny N, Kravitz EA. Biogenic amines and aggression: experimental approaches in crustaceans. Brain Behav Evol 1997; 50 Suppl 1: 60-68 [DOI: 10.1016/S0140-6736(09)60207-5]
4. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-307 [DOI: 10.1016/S0168-8278(00)80371-2]
5. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [DOI: 10.1053/gast.2002.35352]
6. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180 [DOI: 10.1053/gast.2000.8559]
7. Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473 [DOI: 10.1053/jhep.2002.34740]
8. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, Byun KS, Lee CH. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-1495 [DOI: 10.1136/gut.2005.077099]
9. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010; 25: 1374-1380 [DOI: 10.1111/j.1440-1746.2010.06381.x]
10. Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAgchronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol 2010; 25: 54-60 [DOI: 10.1111/j.1440-1746.2009.05952.x]
11. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [DOI: 10.1056/NEJMoa033364]
12. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [DOI: 10.1007/s12072-008-9080-3]
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [DOI: 10.1002/hep.23190]
14. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [DOI: 10.1016/j.jhep.2008.10.001]
15. Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther 2012 Mar 26 [DOI: 10.1111/j.1365-2036.2012.05059.x]
16. Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol 2011; 17: 4804-4809 [DOI: 10.3748/wjg.v17.i43.4804]
17. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695 [DOI: 10.1056/NEJMoa043470]
18. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210